Ocrevus

What's on neurologists' minds? Not drug names, survey shows

Neurologists think more in terms of drug class and indication than brand names, according to a survey with implications for how marketers communicate.

Nick Paul Taylor Jul 18, 2025 10:10am

Roche's high-dose version of Ocrevus flunks phase 3 trial

Apr 2, 2025 3:26pm

Collage poster study of businessmen picture chart arrow goes up

MS meds send CNS market toward strongest growth in years

Mar 26, 2025 10:48am

Roche's Vabysmo will rise above Eylea biosim threat, exec says

Oct 23, 2024 11:24am

Roche doubles down with subcutaneous FDA nod for MS star Ocrevus

Sep 13, 2024 1:50pm

Roches headquarters in Basel sunset in the background

Sales for Roche's Vabysmo rise again, but momentum is stalled

Jul 25, 2024 11:45am